Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies.
04/10/11Neuralstem shares jump over 13% on new stem cell patent
16/12/10Neuralstem Receives FDA Approval to Start Phase Ia Trial for Depression Drug
14/09/10Study Shows Neuralstem’s Stem Cells May Have Application To Treating Stroke
Recent Sector News
U.S. stocks stretched gains, with Nasdaq touching a 15-year high, as Google, Microsoft, and Amazon surged after reporting results. The S&P 500 (INDEXSP:.INX) rose 0.3 percent to 2,118 at 3:43 p.m. in New York. The 30-company Dow Jones Industrial Average (INDEXDJX:.DJI) inched up 0.2 percent to 18,086. The Nasdaq Composite (INDEXNASDAQ:.IXIC) advanced 0.7 percent to 5,093.
Teva’s Board unanimously approved the transaction, which could be finalized by the end of the year. However, Teva will face some obstacles as not have a smooth path as Mylan’s unsolicited US28.9 billion bid for Perrigo Co. (NYSE:PRGO) on April 17 was meant to act as a buttress, making the Canonsburg (PA) run company too big for Teva to swallow.
Pivotal has a total of eight patent applications, of which one has been issued and two allowed so far. Several more patent allowances are anticipated in 2015. The patents could open a window of opportunity for Pivotal, as big pharma companies seek potential licensing deals to extend their current anti-obesity and cholesterol-reducing drug pipelines.
U.S. stock futures were higher today as investors cheered news of General Electric’s comprehensive restructuring plan, including a sale of the bulk of its financial business and a hefty stock repurchase initiative. Futures for the Dow Jones Industrial Average rose 0.2 percent to 17,923, while those for the S&P 500 index added 0.2 percent to 2,089. Futures for the Nasdaq-100 index were basically flat at 4,400.
The oil and gas giant Royal Dutch Shell PLC (LON:RDSB)announced it would buy BG Group PLC for some $70 billion. The deal would result in the world’s largest independent producer of liquefied natural gas. The stock was trading 5-7 percent lower in London in the GBP2,050-2,060 range.
U.S. stock-index futures advanced, signalling the Standard & Poor’s 500 Index will climb for a third day amid deal activity and optimism weak data may delay a rate increase. Futures for the Dow Jones Industrial Average inched up 4 points to 17,809, while those for the S&P 500 index dipped 0.7 point to 2,072.50. Futures for the Nasdaq-100 rose 2.75 points to 4,345.
Investors interested in Neuralstem recently viewed
- Sphere Medical (AIM: SPHR) Raising the Standard of Critical Care
- Ergomed (AIM: ERGO) Drug development services and portfolio of co-development partnerships
- Abzena (AIM: ABZA) Enabling better biopharmiceuticals
- Alliance Pharma (AIM: APH) Prescription branded medicines in the human medical and dental sectors
- iSonea Limited (ASX: ISN) From Wheeze Identification to Wheeze Quantification